Personalized medicine Oncology
The addition of selpercatinib to platinum chemotherapy and pemetrexed doubled progression-free survival (PFS) in patients with advanced or metastatic non-small cell lung cancer (NSCLC) positive for RET gene fusions, regardless of inclusion or not of pembrolizumab in the therapeutic scheme.
Study results LIBRETTO-431, presented at ESMO Congress 2023support the use of selpercatinib as a first-line choice and are likely to expand NSCLC patients’ access to this therapy by favoring coverage by health insurance systems.
The main conclusions:
Median PFS was nearly 25 months with selpercatinib in combination with chemotherapy and pembrolizumab, compared with more than 11 months in the control group, after a median follow-up of nearly 20 months
the benefits of adding selpercatinib on PFS were similar in the groups of patients who did not receive pembrolizumab
the time to CNS relapses was increased by 72% with the use of selpercatinib
administration of selpercatinib improved the objective response rate, the duration of the response to therapy, in relation to the control group, the observed adverse effects were similar to those previously reported during the investigation of selpercatinib therapy
The LIBRETTO-431 phase III clinical trial investigating selpercatinib therapy has so far included more than 250 patients with advanced or metastatic NSCLC positive for RET gene fusions. Selpercatinib is a highly selective inhibitor of the RET tyrosine kinase.
RET gene fusions are present in approximately 2% of NSCLC tumors. Although these mutations are rare, the identification of individuals whose tumors present these fusions is important, because administration of RET inhibitors has important benefits in this group of patients.
Read also:
2023-11-16 16:17:06
#ESMO23 #Selpercatinib #doubles #survival #patients #advanced #metastatic #NSCLC #positive #RET #fusions
